CSPC PHARMACEUTICAL(1093.HK)：TWO MORE LARGE-SCALE BD DEALS ANTICIPATED IN 2H25
Ge Long Hui·2025-08-26 19:16
EGFR ADC (SYS6010): a near-term BD catalyst. SYS6010 is currently in global Ph3 development. In China, two pivotal studies are ongoing: a Ph3 trial comparing SYS6010 to chemotherapy in 2L EGFR TKI-resistant NSCLC, and a Ph1b/3 trial evaluating SYS6010 + osimertinib vs osimertinib alone in 1L EGFR-mutant NSCLC, with the Ph3 portion to start by end-2025. The Company is also in discussion with CDE regarding the initiation of SYS6010 in 2L+ EGFR wild-type NSCLC, with additional Ph3 trials in ESCC and HNSCC in p ...